# EDGAR Filing Document

**Accession Number:** 0000312070
**File Stem:** 0000950103-25-016440
**Filing Date:** 2025-12
**Character Count:** 81034
**Document Hash:** 0dc946c3f662b2cffdbc101883e36ece
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-016440.hdr.sgml**: 20251222

**ACCESSION NUMBER**: 0000950103-25-016440

**CONFORMED SUBMISSION TYPE**: 424B2

**PUBLIC DOCUMENT COUNT**: 20

**FILED AS OF DATE**: 20251222

**DATE AS OF CHANGE**: 20251222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BARCLAYS BANK PLC
- **CENTRAL INDEX KEY:** 0000312070
- **STANDARD INDUSTRIAL CLASSIFICATION:** COMMERCIAL BANKS, NEC [6029]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B2
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287303
- **FILM NUMBER:** 251593334

**BUSINESS ADDRESS:**
- **STREET 1:** 1 CHURCHILL PLACE
- **STREET 2:** CANARY WHARF
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** E14 5HP
- **BUSINESS PHONE:** 0044-20-3555-4619

**MAIL ADDRESS:**
- **STREET 1:** 1 CHURCHILL PLACE
- **STREET 2:** CANARY WHARF
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** E14 5HP

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BARCLAYS BANK PLC /ENG/
- **DATE OF NAME CHANGE:** 19990402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BARCLAYS BANK INTERNATIONAL LTD
- **DATE OF NAME CHANGE:** 19850313

---

| | |
|:---|:---|
| **Term Sheet**<br>**(To the Prospectus dated May 15, 2025, the Prospectus Supplement dated May 15, 2025 and Product Supplement EQUITY ARN-1 dated October 29, 2025)**<br>| **Filed Pursuant to Rule 424(b)(2)<br> Registration Statement No. 333-287303** |

---

---

| | | |
|:---|:---|:---|
| 2,098,702 Units<br>$10 principal amount per unit<br> CUSIP No. 06748V253 | Pricing Date<br>Settlement Date<br>Maturity Date<br>| December 18, 2025<br> December 26, 2025<br> February 26, 2027 |
| ![](image_001.jpg) |  |  |

---

**Accelerated Return Notes<sup>®</sup> Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF**<br>▪Maturity of approximately 14 months<br>▪3-to-1 upside exposure to increases in the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF (the "Market Measure"), subject to a capped return of 27.10%<br>▪1-to-1 downside exposure to decreases in the Market Measure, with 100% of your principal at risk<br>▪All payments occur at maturity and are subject to the credit risk of Barclays Bank PLC.<br>▪No periodic interest payments<br>▪In addition to the underwriting discount set forth below, the notes include a hedging-related charge of $0.05 per unit. See "Structuring the Notes."<br>▪Limited secondary market liquidity, with no exchange listing<br>▪The notes are our unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC. The notes are not covered by the U.K. Financial Services Compensation Scheme or insured by the U.S. Federal Deposit Insurance Corporation or any other governmental agency or deposit insurance agency of the United States, the United Kingdom, or any other jurisdiction.<br>

**The notes are being issued by Barclays Bank PLC ("Barclays"). There are important differences between the notes and a conventional debt security, including different investment risks and certain additional costs. See "Risk Factors" and "Additional Risk Factors" beginning on page TS-7 of this term sheet and "Risk Factors" beginning on page PS-7 of product supplement EQUITY ARN-1 and beginning on page S-9 of the prospectus supplement.**

**Our initial estimated value of the notes, based on our internal pricing models, is $9.675 per unit on the pricing date, which is less than the public offering price listed below.** See "Summary" on the following page, "Risk Factors" beginning on page TS-7 of this term sheet and "Structuring the Notes" below for additional information. The actual value of your notes at any time will reflect many factors and cannot be predicted with accuracy.

**Notwithstanding and to the exclusion of any other term of the notes or any other agreements, arrangements or understandings between Barclays and any holder or beneficial owner of the notes (or the trustee on behalf of the holders of the notes), by acquiring the notes, each holder or beneficial owner of the notes acknowledges, accepts, agrees to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority. All payments are subject to the risk of exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority. See "Consent to U.K. Bail-in Power" on page TS-3 and "Risk Factors" beginning on page TS-7 of this term sheet.**

None of the Securities and Exchange Commission (the "SEC"), any state securities commission, or any other regulatory body has approved or disapproved of these securities or determined if this Note Prospectus (as defined below) is truthful or complete. Any representation to the contrary is a criminal offense.

---

| | | |
|:---|:---|:---|
|  | <u>Per Unit</u> | <u>Total</u> |
| Public offering price<sup></sup> | $10.000 | $20987020.00 |
| Underwriting discount<sup></sup> | $0.175 | $367272.85 |
| Proceeds, before expenses, to Barclays<sup></sup> | $9.825 | $20619747.15 |

---

**The notes:**

---

| | | |
|:---|:---|:---|
| **Are Not FDIC Insured** | **Are Not Bank Guaranteed** | **May Lose Value** |

---

**BofA Securities** 

December 18, 2025

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Summary

The Accelerated Return Notes<sup>®</sup> Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027 (the "notes") are our unsecured and unsubordinated obligations and are not deposit liabilities of Barclays. The notes are not covered by the U.K. Financial Services Compensation Scheme or insured by the U.S. Federal Deposit Insurance Corporation or any other governmental agency or deposit insurance agency of the United States, the United Kingdom or any other jurisdiction. **The notes will rank equally with all of our other unsecured and unsubordinated debt. Any payments due on the notes, including any repayment of principal, will be subject to the credit risk of Barclays and to the risk of exercise of any U.K. Bail-in Power (as described herein) or any other resolution measure by any relevant U.K. resolution authority.**

The notes provide you a leveraged return, subject to a cap, if the Ending Value of the Market Measure, which is the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF (the "Market Measure"), is greater than the Starting Value. If the Ending Value is less than the Starting Value, you will lose all or a portion of the principal amount of your notes. Any payments on the notes will be calculated based on the $10 principal amount per unit and will depend on the performance of the Market Measure, subject to our credit risk. See "Terms of the Notes" below.

On the cover page of this term sheet, we have provided the estimated value for the notes. This estimated value was determined based on our internal pricing models, which take into account a number of variables, including volatility, interest rates and our internal funding rates, which are our internally published borrowing rates and the economic terms of certain related hedging arrangements. This estimated value is less than the public offering price.

The economic terms of the notes (including the Capped Value) are based on our internal funding rates, which may vary from the levels at which our benchmark debt securities trade in the secondary market, and the economic terms of certain related hedging arrangements. The difference between these rates, as well as the underwriting discount, the hedging-related charge and other amounts described below, reduced the economic terms of the notes. For more information about the estimated value and the structuring of the notes, see "Structuring the Notes" below.

---

| | | |
|:---|:---|:---|
| Terms of the Notes | Terms of the Notes | Redemption Amount Determination |
| **Issuer:** | Barclays Bank PLC ("Barclays") | On the maturity date, you will receive a cash payment per unit determined as follows: |
| **Principal Amount:** | $10.00 per unit |  |
| **Term:** | Approximately 14 months |  |
| **Market Measure:** | The State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF (Bloomberg symbol: "XBI") |  |
| **Starting Value:** | $120.01 |  |
| **Ending Value:** | The average of the Closing Market Price of the Market Measure *times* the Price Multiplier on each calculation day occurring during the Maturity Valuation Period. The scheduled calculation days are subject to postponement in the event of Market Disruption Events, as described beginning on page PS-27 of product supplement EQUITY ARN-1. |  |
| **Price Multiplier:** | 1, subject to adjustment for certain events relating to the Market Measure, as described beginning on page PS-30 of product supplement EQUITY ARN-1 |  |
| **Participation Rate:** | 300% |  |
| **Capped Value:** | $12.71 per unit, which represents a return of 27.10% over the principal amount |  |
| **Maturity Valuation Period:** | February 17, 2027, February 18, 2027, February 19, 2027, February 22, 2027 and February 23, 2027 |  |
| **Fees and Charges:** | The public offering price of the notes includes the underwriting discount of $0.175 per unit listed on the cover page and a hedging-related charge of $0.05 per unit described in "Structuring the Notes" below. |  |
| **Calculation Agents:** | Barclays and BofA Securities, Inc. ("BofAS") |  |

---

Accelerated Return Notes<sup>®</sup> TS-2

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

The terms and risks of the notes are contained in this term sheet and in the following:

▪ Product supplement EQUITY ARN-1 dated October 29, 2025:<br> [http://www.sec.gov/Archives/edgar/data/312070/000095010325013808/dp236328_424b2-equityarn1.htm](http://www.sec.gov/Archives/edgar/data/312070/000095010325013808/dp236328_424b2-equityarn1.htm)

▪ Series A MTN prospectus supplement dated May 15, 2025:<br> [http://www.sec.gov/Archives/edgar/data/312070/000095010325006051/dp228678_424b2-prosupp.htm](http://www.sec.gov/Archives/edgar/data/312070/000095010325006051/dp228678_424b2-prosupp.htm)

▪ Prospectus dated May 15, 2025:<br> [http://www.sec.gov/Archives/edgar/data/312070/000119312525120720/d925982d424b2.htm](http://www.sec.gov/Archives/edgar/data/312070/000119312525120720/d925982d424b2.htm)

These documents (together, the "Note Prospectus") have been filed as part of a registration statement with the SEC, which may, without cost, be accessed on the SEC website as indicated above or obtained from us, Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") or BofAS by calling 1-800-294-1322. Before you invest, you should read the Note Prospectus, including this term sheet, and the other documents that we have filed with the SEC for information about us and this offering. Any prior or contemporaneous oral statements and any other written materials you may have received are superseded by the Note Prospectus. Capitalized terms used but not defined in this term sheet have the meanings set forth in product supplement EQUITY ARN-1. Unless otherwise indicated or unless the context requires otherwise, all references in this term sheet to "we," "us," "our" or similar references are to Barclays.

"Accelerated Return Notes<sup>®</sup>" and "ARNs<sup>®</sup>" are the registered service marks of Bank of America Corporation, the parent company of MLPF&S and BofAS.

Consent to U.K. Bail-in Power

**Notwithstanding and to the exclusion of any other term of the notes or any other agreements, arrangements or understandings between us and any holder or beneficial owner of the notes (or the trustee on behalf of the holders of the notes), by acquiring the notes, each holder or beneficial owner of the notes acknowledges, accepts, agrees to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority.**

Under the U.K. Banking Act 2009, as amended, the relevant U.K. resolution authority may exercise a U.K. Bail-in Power in circumstances in which the relevant U.K. resolution authority is satisfied that the resolution conditions are met. These conditions include that a U.K. bank or investment firm is failing or is likely to fail to satisfy the Financial Services and Markets Act 2000 (the "FSMA") threshold conditions for authorization to carry on certain regulated activities (within the meaning of section 55B FSMA) or, in the case of a U.K. banking group company that is a European Economic Area ("EEA") or third country institution or investment firm, that the relevant EEA or third country relevant authority is satisfied that the resolution conditions are met in respect of that entity.

The U.K. Bail-in Power includes any write-down, conversion, transfer, modification and/or suspension power, which allows for (i) the reduction or cancellation of all, or a portion, of the principal amount of, or interest on, or any other amounts payable on, the notes; (ii) the conversion of all, or a portion, of the principal amount of, or interest on, or any other amounts payable on, the notes into shares or other securities or other obligations of Barclays or another person (and the issue to, or conferral on, the holder or beneficial owner of the notes of such shares, securities or obligations); (iii) the cancellation of the notes and/or (iv) the amendment or alteration of the maturity of the notes, or the amendment of the amount of interest or any other amounts due on the notes, or the dates on which interest or any other amounts become payable, including by suspending payment for a temporary period; which U.K. Bail-in Power may be exercised by means of a variation of the terms of the notes solely to give effect to the exercise by the relevant U.K. resolution authority of such U.K. Bail-in Power. Each holder and beneficial owner of the notes further acknowledges and agrees that the rights of the holders or beneficial owners of the notes are subject to, and will be varied, if necessary, solely to give effect to, the exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority. For the avoidance of doubt, this consent and acknowledgment is not a waiver of any rights holders or beneficial owners of the notes may have at law if and to the extent that any U.K. Bail-in Power is exercised by the relevant U.K. resolution authority in breach of laws applicable in England.

For more information, please see "Risk Factors—Issuer-related Risks—You May Lose Some or All of Your Investment If Any U.K. Bail-in Power Is Exercised by the Relevant U.K. Resolution Authority" in this term sheet as well as "U.K. Bail-in Power," "Risk Factors—Risks Relating to the Securities Generally—Regulatory action in the event a bank or investment firm in the Group is failing or likely to fail, including the exercise by the relevant U.K. resolution authority of a variety of statutory resolution powers, could materially adversely affect the value of any securities" and "Risk Factors—Risks Relating to the Securities Generally—Under the terms of the securities, you have agreed to be bound by the exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority" in the accompanying prospectus supplement.

Accelerated Return Notes<sup>®</sup> TS-3

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Investor Considerations

**You may wish to consider an investment in the notes if:**

▪ You anticipate that the Market Measure will increase moderately from the Starting Value to the Ending Value.

▪ You are willing to risk a loss of principal and return if the Market Measure decreases from the Starting Value to the Ending Value.

▪ You accept that the return on the notes will be capped.

▪ You are willing to forgo the interest payments that are paid on conventional interest-bearing debt securities.

▪ You are willing to forgo dividends and other benefits of directly owning shares of the Market Measure or the securities held by the
Market Measure.

▪ You are willing to accept a limited or no market for sales prior to maturity, and understand that the market prices for the notes,
if any, will be affected by various factors, including our actual and perceived creditworthiness, the inclusion in the public offering
price of the underwriting discount, the hedging-related charge and other amounts, as described above.

▪ You are willing and able to assume our credit risk, as issuer of the notes, for all payments under the notes, including the Redemption
Amount.

▪ You are willing and able to consent to the exercise of any U.K. Bail-in Power by U.K. resolution authorities.

**The notes may not be an appropriate investment for you if:**

▪ You believe that the Market Measure will decrease from the Starting Value to the Ending Value or that it will not increase sufficiently
over the term of the notes to provide you with your desired return.

▪ You seek principal repayment or preservation of capital.

▪ You seek an uncapped return on your investment.

▪ You seek interest payments or other current income on your investment.

▪ You want to receive dividends or have other benefits of directly owning shares of the Market Measure or the securities held by the
Market Measure.

▪ You seek an investment for which there will be a liquid secondary market.

▪ You are unwilling or unable to take market risk on the notes or to take our credit risk as issuer of the notes.

▪ You are unwilling or unable to consent to the exercise of any
U.K. Bail-in Power by U.K. resolution authorities.

<br> We urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the notes.

Accelerated Return Notes<sup>®</sup> TS-4

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Hypothetical Payout Profile and Examples of Payments at Maturity

---

| | |
|:---|:---|
| **Accelerated Return Notes<sup>®</sup>**<br>![](image_003.jpg)<br>| This graph reflects the returns on the notes, based on the Participation Rate of 300% and the Capped Value of $12.71 per unit. The green line reflects the returns on the notes, while the dotted gray line reflects the returns of a direct investment in the Market Measure, excluding dividends.<br>This graph has been prepared for purposes of illustration only.<br>|

---

The following table and examples are for purposes of illustration only. They are based on **hypothetical** values and show **hypothetical** returns on the notes. They illustrate the calculation of the Redemption Amount and total rate of return based on a hypothetical Starting Value of 100.00, the Participation Rate of 300%, the Capped Value of $12.71 per unit and a range of hypothetical Ending Values. **The actual amount you receive and the resulting total rate of return will depend on the actual Starting Value and Ending Value, and whether you hold the notes to maturity.** The following examples do not take into account any tax consequences from investing in the notes.

For recent actual prices of the Market Measure, see "The Market Measure" section below. The Ending Value will not include any income generated by dividends paid on the Market Measure, which you would otherwise be entitled to receive if you invested in the Market Measure directly. In addition, all payments on the notes are subject to issuer credit risk.

---

| | | | |
|:---|:---|:---|:---|
| **Ending Value** | **Percentage Change**<br> **from the Starting Value**<br> **to the Ending Value** | **Redemption Amount**<br> **per Unit** | **Total Rate of Return**<br> **on the Notes** |
| 0.00 | -100.00% | $0.00 | -100.00% |
| 50.00 | -50.00% | $5.00 | -50.00% |
| 70.00 | -30.00% | $7.00 | -30.00% |
| 80.00 | -20.00% | $8.00 | -20.00% |
| 90.00 | -10.00% | $9.00 | -10.00% |
| 95.00 | -5.00% | $9.50 | -5.00% |
| 97.00 | -3.00% | $9.70 | -3.00% |
| &nbsp;&nbsp;&nbsp;&nbsp;100.00<sup>(1)</sup> | 0.00% | $10.00 | 0.00% |
| 102.00 | 2.00% | $10.60 | 6.00% |
| 103.00 | 3.00% | $10.90 | 9.00% |
| 105.00 | 5.00% | $11.50 | 15.00% |
| 109.04 | 9.04% | &nbsp;&nbsp;&nbsp;&nbsp;$12.71<sup>(2)</sup> | 27.10% |
| 110.00 | 10.00% | $12.71 | 27.10% |
| 120.00 | 20.00% | $12.71 | 27.10% |
| 130.00 | 30.00% | $12.71 | 27.10% |
| 150.00 | 50.00% | $12.71 | 27.10% |
| 200.00 | 100.00% | $12.71 | 27.10% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The **hypothetical** Starting Value of 100.00 used in these examples has been chosen for illustrative purposes only, and does not
represent the actual Starting Value for the Market Measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The Redemption Amount per unit cannot exceed the Capped Value.

Accelerated Return Notes<sup>®</sup> TS-5

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

**Redemption Amount Calculation Examples:**

---

| | |
|:---|:---|
| **Example 1** |  |
| The Ending Value is 50.00, or 50.00% of the Starting Value: | The Ending Value is 50.00, or 50.00% of the Starting Value: |
| Starting Value: 100.00 | Starting Value: 100.00 |
| Ending Value: 50.00 | Ending Value: 50.00 |
| ![](image_004.jpg)<br>| **= $5.00** Redemption Amount per unit |

---

---

| | |
|:---|:---|
| **Example 2** |  |
| The Ending Value is 102.00, or 102.00% of the Starting Value: | The Ending Value is 102.00, or 102.00% of the Starting Value: |
| Starting Value: 100.00 |  |
| Ending Value: 102.00 |  |
| ![](image_005.jpg)<br>| **= $10.60** Redemption Amount per unit |

---

---

| | |
|:---|:---|
| **Example 3** |  |
| The Ending Value is 130.00, or 130.00% of the Starting Value: | The Ending Value is 130.00, or 130.00% of the Starting Value: |
| Starting Value: 100.00 |  |
| Ending Value: 130.00 |  |
| ![](image_006.jpg)<br>| **= $19.00, however, because the Redemption Amount for the notes cannot exceed the Capped Value, the Redemption Amount will be $12.71 per unit** |

---

Accelerated Return Notes<sup>®</sup> TS-6

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Risk Factors

*There are important differences between the notes and a conventional debt security. An investment in the notes involves significant risks, including those listed below. You should carefully review the more detailed explanation of risks relating to the notes in the "Risk Factors" sections beginning on page PS-7 of product supplement EQUITY ARN-1 and page S-9 of the Series A MTN prospectus supplement identified above. We also urge you to consult your investment, legal, tax, accounting, and other advisors before you invest in the notes.*

**<u>Structure-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Depending on the performance of the Market Measure as measured shortly before the maturity date, your investment may result in a loss;
there is no guaranteed return of principal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Your return on the notes may be less than the yield you could earn by owning a conventional fixed or floating rate debt security of
comparable maturity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Your investment return is limited to the return represented by the Capped Value and may be less than a comparable investment directly
in shares of the Market Measure or the securities held by the Market Measure.

**<u>Issuer-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Payments on the notes are subject to our credit risk, and any actual or perceived changes in our creditworthiness are expected to
affect the value of the notes. If we become insolvent or are unable to pay our obligations, you may lose your entire investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ You may lose some or all of your investment if any U.K. Bail-in Power is exercised by the relevant U.K. resolution authority. Notwithstanding
and to the exclusion of any other term of the notes or any other agreements, arrangements or understandings between Barclays and any holder
or beneficial owner of the notes (or the trustee on behalf of the holders of the notes), by acquiring the notes, each holder or beneficial
owner of the notes acknowledges, accepts, agrees to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant
U.K. resolution authority as set forth under "Consent to U.K. Bail-in Power" in this term sheet. Accordingly, any U.K. Bail-in
Power may be exercised in such a manner as to result in you and other holders and beneficial owners of the notes losing all or a part
of the value of your investment in the notes or receiving a different security from the notes, which may be worth significantly less than
the notes and which may have significantly fewer protections than those typically afforded to debt securities. Moreover, the relevant
U.K. resolution authority may exercise the U.K. Bail-in Power without providing any advance notice to, or requiring the consent of, the
holders and beneficial owners of the notes. The exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority with respect
to the notes will not be a default or an Event of Default (as each term is defined in the senior debt securities indenture) and the trustee
will not be liable for any action that the trustee takes, or abstains from taking, in either case, in accordance with the exercise of
the U.K. Bail-in Power by the relevant U.K. resolution authority with respect to the notes. See "Consent to U.K. Bail-in Power"
in this term sheet as well as "U.K. Bail-in Power," "Risk Factors—Risks Relating to the Securities Generally—Regulatory
action in the event a bank or investment firm in the Group is failing or likely to fail, including the exercise by the relevant U.K. resolution
authority of a variety of statutory resolution powers, could materially adversely affect the value of any securities" and "Risk
Factors—Risks Relating to the Securities Generally—Under the terms of the securities, you have agreed to be bound by the exercise
of any U.K. Bail-in Power by the relevant U.K. resolution authority" in the accompanying prospectus supplement.

**<u>Valuation- and Market-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The estimated value of your notes is based on our internal pricing models. Our internal pricing models take into account a number
of variables and are based on a number of subjective assumptions, which may or may not materialize, typically including volatility, interest
rates, and our internal funding rates. These variables and assumptions are not evaluated or verified on an independent basis and may prove
to be inaccurate. Different pricing models and assumptions of different financial institutions could provide valuations for the notes
that are different from our estimated value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The estimated value is based on a number of variables, including volatility, interest rates and our internal funding rates. Our internal
funding rates may vary from the levels at which our benchmark debt securities trade in the secondary market. As a result of this difference,
the estimated value referenced in this term sheet may be lower if such estimated value was based on the levels at which our benchmark
debt securities trade in the secondary market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The estimated value of your notes is lower than the public offering price of your notes. This difference is a result of certain factors,
such as the inclusion in the public offering price of the underwriting discount, the hedging-related charge, the estimated profit, if
any, that we or any of our affiliates expect to earn in connection with structuring the notes, and the estimated cost which we may incur
in hedging our obligations under the notes, as further described in "Structuring the Notes" below. If you attempt to sell
the notes prior to maturity, their market value may be lower than the price you paid for the notes and lower than the estimated value
because the secondary market prices take into consideration the levels at which our debt securities trade in the secondary market, but
do not take into account such fees, charges and other amounts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The estimated value of the notes is not a prediction of the prices at which MLPF&S, BofAS or its affiliates, or any of our affiliates
or any other third parties may be willing to purchase the notes from you in secondary market transactions. The

Accelerated Return Notes<sup>®</sup> TS-7

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

price at which you may be able to sell your notes in the secondary market at any time will be influenced by many factors that cannot be predicted, such as market conditions, and any bid and ask spread for similar size trades, and may be substantially less than our estimated value of the notes. Any sale prior to the maturity date could result in a substantial loss to you.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ A trading market is not expected to develop for the notes. None of us, MLPF&S, BofAS or our respective affiliates is obligated
to make a market for, or to repurchase, the notes. There is no assurance that any party will be willing to purchase your notes at any
price in any secondary market.

**<u>Conflict-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Our business, hedging and trading activities, and those of MLPF&S, BofAS and our respective affiliates (including trades in shares
of the Market Measure or the securities held by the Market Measure), and any hedging and trading activities we, MLPF&S, BofAS or our
respective affiliates engage in for our clients' accounts, may affect the market value and return of the notes and may create conflicts
of interest with you.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ There may be potential conflicts of interest involving the calculation agents, which are Barclays and BofAS. We have the right to
appoint and remove the calculation agents.

**<u>Market Measure-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The sponsor and advisor of the Market Measure may adjust the Market Measure in a way that could adversely affect the value of the
notes and the amount payable on the notes, and these entities have no obligation to consider your interests.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ You will have no rights of a holder of shares of the Market Measure or the securities held by the Market Measure, and you will not
be entitled to receive securities or dividends or other distributions by the issuers of those securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ While we, MLPF&S, BofAS or our respective affiliates may from time to time own shares of the Market Measure or the securities
held by the Market Measure, we, MLPF&S, BofAS and our respective affiliates do not control the Market Measure or the issuers of those
securities, and have not verified any disclosure made by any other company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ There are liquidity and management risks associated with the Market Measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The performance of the Market Measure may not correlate with the performance of the securities held by the Market Measure as well
as the net asset value per share of the Market Measure, especially during periods of market volatility when the liquidity and the market
price of shares of the Market Measure and/or the securities held by the Market Measure may be adversely affected, sometimes materially.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The payments on the notes will not be adjusted for all corporate events that could affect the Market Measure. See "Description
of the ARNs—Anti-Dilution and Discontinuance Adjustments Relating to Underlying Funds" in product supplement EQUITY ARN-1.

**<u>Tax-related Risks</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ The U.S. federal income tax consequences of an investment in the notes are uncertain. There is no direct legal authority regarding
the proper U.S. federal income tax treatment of the notes, and we do not plan to request a ruling from the Internal Revenue Service (the
"IRS"). Consequently, significant aspects of the tax treatment of the notes are uncertain, and the IRS or a court might not
agree with the treatment of the notes as prepaid forward contracts, as described below under "Tax Consequences." If the IRS
were successful in asserting an alternative treatment for the notes, the tax consequences of the ownership and disposition of the notes
could be materially and adversely affected.

Even if the treatment of the notes is respected, the IRS may assert that the notes constitute "constructive ownership transactions" within the meaning of Section 1260 of the Internal Revenue Code of 1986, as amended (the "Code"), in which case gain recognized in respect of the notes that would otherwise be long-term capital gain and that was in excess of the "net underlying long-term capital gain" (as defined in Section 1260) would be treated as ordinary income, and a notional interest charge would apply as if that income had accrued for tax purposes at a constant yield over the notes' term. Our special tax counsel has not expressed an opinion with respect to whether the constructive ownership rules apply to the notes.

In addition, in 2007 the Treasury Department and the IRS released a notice requesting comments on various issues regarding the U.S. federal income tax treatment of "prepaid forward contracts" and similar instruments. Any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You should review carefully the sections of the accompanying prospectus supplement entitled "Material U.S. Federal Income Tax Consequences—Tax Consequences to U.S. Holders—Notes Treated as Prepaid Forward Contracts" and, if you are a non-U.S. holder, "—Tax Consequences to Non-U.S. Holders," and consult your tax advisor regarding the U.S. federal tax consequences of an investment in the notes (including the potential application of the constructive ownership rules, possible alternative treatments and the issues presented by the 2007 notice), as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.

Additional Risk Factors

**The securities held by the Market Measure are concentrated in one industry.** As a result, the securities that will determine the performance of the notes are concentrated in one industry. Although an investment in the notes will not give holders any ownership or other direct interests in the securities held by the Market Measure, the return on the notes will be subject to certain risks similar to those

Accelerated Return Notes<sup>®</sup> TS-8

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

associated with direct equity investments in the biotechnology industry. Accordingly, by investing in the notes, you will not benefit from the diversification which could result from an investment linked to companies that operate in multiple industries.

**Adverse conditions in the biotechnology industry may reduce your return on the notes.** All of the stocks held by the Market Measure are issued by companies whose primary lines of business are directly associated with the biotechnology industry. The profitability of these companies is largely dependent on, among other things, demand for the companies' products, regulatory influences on the biotechnology market (including healthcare reform and receipt of regulatory approvals and compliance with complex regulatory requirements), pricing and reimbursement from third party payors, continued innovation and successful development of new products, talent attraction and retention, maintaining intellectual property rights and industry competition. Any adverse developments affecting the biotechnology industry could adversely affect the price of the Market Measure and the value of the notes.

Accelerated Return Notes<sup>®</sup> TS-9

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

The Market Measure

All information contained in this term sheet regarding the Market Measure has been derived from publicly available information, without independent verification. This information reflects the policies of, and is subject to change by, the SPDR<sup>®</sup> Series Trust and SSGA Funds Management, Inc. ("**SSGA FM**"). The Market Measure is an investment portfolio maintained and managed by SSGA FM, the investment adviser to the Market Measure. The consequences of any discontinuance of the Market Measure are discussed in the section entitled "Description of the ARNs—Anti-Dilution and Discontinuance Adjustments Relating to Underlying Funds" in product supplement EQUITY ARN-1. None of us, the calculation agents, MLPF&S or BofAS accepts any responsibility for the calculation, maintenance or publication of the Market Measure or any successor. Neither we nor any agent has independently verified the accuracy or completeness of any information with respect to the Market Measure in connection with the offer and sale of the notes. The Market Measure is an exchange-traded fund that trades on the NYSE Arca, Inc. under the ticker symbol "XBI."

The Market Measure seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P<sup>®</sup> Biotechnology Select Industry Index. The S&P<sup>®</sup> Biotechnology Select Industry Index is a modified equal-weighted index that is designed to measure the performance of the Global Industry Classification Standard ("**GICS<sup>®</sup>**") biotechnology sub-industry of the S&P Total Market Index. The S&P<sup>®</sup> Biotechnology Select Industry Index may also include companies in the life sciences tools and services supplementary sub-industry. For more information about the S&P<sup>®</sup> Biotechnology Select Industry Index, please see "The S&P<sup>®</sup> Biotechnology Select Industry Index" below.

In seeking to track the performance of the S&P<sup>®</sup> Biotechnology Select Industry Index, the Market Measure employs a "sampling" strategy, which means that the Market Measure is not required to purchase all of the securities represented in the S&P<sup>®</sup> Biotechnology Select Industry Index. Instead, the Market Measure may purchase a subset of the securities in the S&P<sup>®</sup> Biotechnology Select Industry Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics as the S&P Biotechnology Select Industry Index. The quantity of holdings in the Market Measure will be based on a number of factors, including asset size of the Market Measure. Based on its analysis of these factors, SSGA FM either may invest the Market Measure's assets in a subset of securities in the S&P<sup>®</sup> Biotechnology Select Industry Index or may invest the Market Measure's assets in substantially all of the securities represented in the S&P<sup>®</sup> Biotechnology Select Industry Index in approximately the same proportions as the S&P<sup>®</sup> Biotechnology Select Industry Index, as determined by SSGA FM to be in the best interest of the Market Measure in pursuing its objective.

While SSGA FM seeks to track the performance of the S&P<sup>®</sup> Biotechnology Select Industry Index (i.e., achieve a high degree of correlation with the S&P<sup>®</sup> Biotechnology Select Industry Index), the Market Measure's return may not match the return of the S&P<sup>®</sup> Biotechnology Select Industry Index for a number of reasons. For example, the return on the sample of securities purchased by the Market Measure (or the return on securities not included in the S&P<sup>®</sup> Biotechnology Select Industry Index) may not correlate precisely with the return of the S&P<sup>®</sup> Biotechnology Select Industry Index. The Market Measure incurs a number of operating expenses not applicable to the S&P<sup>®</sup> Biotechnology Select Industry Index, and incurs costs in buying and selling securities. In addition, the Market Measure may not be fully invested at times, either as a result of cash flows into or out of the Market Measure or reserves of cash held by the Market Measure to meet redemptions. SSGA FM may attempt to track the S&P<sup>®</sup> Biotechnology Select Industry Index's return by investing in fewer than all of the securities in the S&P<sup>®</sup> Biotechnology Select Industry Index, or in some securities not included in the S&P<sup>®</sup> Biotechnology Select Industry Index, potentially increasing the risk of divergence between the Market Measure's return and that of the S&P<sup>®</sup> Biotechnology Select Industry Index. Changes in the composition of the S&P<sup>®</sup> Biotechnology Select Industry Index and regulatory requirements also may impact the Market Measure's ability to match the return of the S&P Biotechnology Select Industry Index. SSGA FM may apply one or more "screens" or investment techniques to refine or limit the number or types of issuers included in the S&P<sup>®</sup> Biotechnology Select Industry Index in which the Market Measure may invest. Application of such screens or techniques may result in investment performance below that of the S&P<sup>®</sup> Biotechnology Select Industry Index and may not produce results expected by SSGA FM. Index tracking risk may be heightened during times of increased market volatility or other unusual market conditions.

The SPDR<sup>®</sup> Series Trust is a registered investment company that consists of a separate investment portfolio for the Market Measure. Information provided to or filed with the SEC by the SPDR<sup>®</sup> Series Trust pursuant to the Securities Act of 1933, as amended, and the Investment Company Act of 1940, as amended, can be located by reference to SEC file numbers 333-57793 and 811-08839, respectively, through the SEC's website at http://www.sec.gov.

***The S&P****<sup>®</sup> **Biotechnology Select Industry Index***

All information contained in this term sheet regarding the S&P<sup>®</sup> Biotechnology Select Industry Index including, without limitation, its make-up, method of calculation and changes in its components, has been derived from publicly available information, without independent verification. This information reflects the policies of, and is subject to change by, S&P Dow Jones Indices LLC ("**S&P Dow Jones**"). The S&P<sup>®</sup> Biotechnology Select Industry Index is calculated, maintained and published by S&P Dow Jones. S&P Dow Jones has no obligation to continue to publish, and may discontinue publication of, the S&P<sup>®</sup> Biotechnology Select Industry Index.

The S&P<sup>®</sup> Biotechnology Select Industry Index is one of the S&P Select Industry Indices (collectively, the "**Select Industry Indices**" and each, a "**Select Industry Index**"). The Select Industry Indices are modified equal-weighted indices that are designed to measure the performance of stocks composing specific GICS<sup>®</sup> sub-industries or groups of sub-industries in the S&P Total Market Index (the "**S&P TMI**"). Membership is based on a company's GICS<sup>®</sup> classification, as well as liquidity and market capitalization requirements. The S&P<sup>®</sup> Biotechnology Select Industry Index is designed to measure the performance of the GICS<sup>®</sup> biotechnology sub-industry of the S&P TMI. The S&P<sup>®</sup> Biotechnology Select Industry Index may also include companies in the life sciences tools & services supplementary

Accelerated Return Notes<sup>®</sup> TS-10

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

sub-industry. The S&P<sup>®</sup> Biotechnology Select Industry Index is reported by Bloomberg L.P. under the ticker symbol "SPSIBI." For additional information about the S&P TMI, please see "The S&P Total Market Index" below.

***The S&P Total Market Index***

The S&P TMI offers broad market exposure to companies of all market capitalizations, including all eligible U.S. common equities with a primary listing on the New York Stock Exchange, NYSE Arca, NYSE American, Nasdaq Global Select Market, Nasdaq Select Market, Nasdaq Capital Market, Cboe BZX, Cboe BYX, Cboe EDGA or Cboe EDGX exchanges. Only U.S. companies are eligible for inclusion in the S&P TMI.

***The S&P<sup>®</sup> Select Industry Indices***

**Select Industry Index Eligibility**

To qualify for membership in a Select Industry Index, at each quarterly rebalancing, a company must satisfy the following criteria:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· be
a member of the S&P TMI;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· be
included in the relevant GICS<sup>®</sup> sub-industries for the relevant Select Industry Index (stocks included in such sub-industry,
" **primary stocks** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· meet
one of the following float-adjusted market capitalization ()"**FMC**") and float-adjusted liquidity ratio ()"**FALR** ")
requirements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· be
a current constituent, have an FMC greater than or equal to US$300 million and have an FALR greater than or equal to 50%;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· have
an FMC greater than or equal to US$500 million and an FALR greater than or equal to 90%; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· have
an FMC greater than or equal to US$400 million and an FALR greater than or equal to 150%.

Notwithstanding the foregoing, to be eligible for inclusion in the S&P<sup>®</sup> Banks Select Industry Index, a company's FMC must be above US$2 billion and its FALR must be above 100%, and existing constituents of the S&P<sup>®</sup> Banks Select Industry Index are removed at the quarterly rebalancing date if either their FMC falls below US$1 billion or their FALR falls below 50%.

In the event that fewer than 35 stocks are selected for each Select Industry Index using the eligible primary stocks, certain indices will select stocks for inclusion from a supplementary list of highly correlated sub-industries (supplementary stocks) based on a process established by S&P Dow Jones. Additionally, minimum FMC requirements may be relaxed for all Select Industry Indices to ensure that there are at least 22 stocks in each Select Industry Index as of each rebalancing effective date.

*Liquidity.* An FALR, defined as the annual dollar value traded divided by the FMC, is used to measure liquidity. Using composite pricing and all publicly reported U.S. consolidated volume, annual dollar value traded is defined as the average closing price multiplied by the historical volume over the 365 calendar days prior to the evaluation date. This is reduced to the available trading period for stocks that do not have 365 calendar days of trading history. In these cases, the dollar value traded available as of the evaluation date is annualized. Liquidity requirements are reviewed during the quarterly rebalancings. The price, shares outstanding and IWF (as defined below) as of the evaluation date are used to calculate the FMC. The evaluation date is the last business day of the month prior to the rebalancing effective date.

*Takeover Restrictions.* At the discretion of S&P Dow Jones, constituents with shareholder ownership restrictions defined in company bylaws may be deemed ineligible for inclusion in a Select Industry Index. Ownership restrictions preventing entities from replicating the index weight of a stock may be excluded from the eligible universe or removed from the relevant Select Industry Index. S&P Dow Jones will provide up to five days advance notification of a deletion between rebalancings due to ownership restrictions. If S&P Dow Jones's index committee (the "**Index Committee**") decides to remove or exclude a company, that company is ineligible for re-entry or inclusion, respectively, for at least one full calendar year, beginning with the subsequent rebalance.

*Multiple Share Classes.* Some companies in the S&P TMI are represented by multiple share classes. As of December 2015, each company in the Select Industry Indices is represented once by the primary listing, which is generally the most liquid share line.

**Calculation of the Select Industry Indices**

The Select Industry Indices are equal-weighted, with adjustments to individual constituent weights to ensure concentration and liquidity requirements, and calculated by means of the divisor methodology used by S&P Dow Jones for the Select Industry Indices.

The index value of each Select Industry Index is simply the market value of that Select Industry Index divided by the index divisor:

Index Value = (Index Market Value) / Divisor

Index Market Value =![](image_007.jpg)

where *N* is the number of stocks in the index, P<sub>i</sub> is the price of stock *i*, Shares<sub>i</sub> is total shares outstanding of stock *i*, IWF<sub>i</sub> is the float factor of stock *i* (as defined below), and AWF<sub>i</sub> is the adjustment factor of stock *i* assigned at each index rebalancing date, *t*, which makes all index constituents modified market capitalization equal (and, therefore, equal weight), while maintaining the total market value of the overall index. The AWF for each index constituent, *i*, at rebalancing date, *t*, is calculated by:

Accelerated Return Notes<sup>®</sup> TS-11

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

AWF<sub>i,t</sub> = Z / (N × FloatAdjustedMarketValue<sub>i,t</sub>)

where Z is an index-specific constant set for the purpose of deriving the AWF and, therefore, each stock's share count used in the index calculation (often referred to as modified index shares).

*Float Adjustment.* Float adjustment means that the number of shares outstanding is reduced to exclude shares that are held by other publicly traded companies, government agencies or certain types of strategic shareholders from the calculation of the index value because such shares are not available to investors. The goal of float adjustment is to adjust each company's total shares outstanding for long-term strategic shareholders, who often have interests such as maintaining control rather than securing the shorter-term economic fortunes of the company. Generally, these long-term strategic shareholders include, but are not limited to, officers and directors, private equity, venture capital and special equity firms, asset managers and insurance companies with direct board of director representation, other publicly traded companies that hold shares, holders of restricted shares, company-sponsored employee share plans/trusts, defined contribution plans/savings, and investment plans, foundations or family trusts associated with the company, government entities at all levels (other than government retirement/pension funds), sovereign wealth funds and any individual person who controls a 5% or greater stake in a company as reported in regulatory filings. Restricted shares are generally not included in total shares outstanding except for shares held as part of a lock-up agreement. Shares that are not considered outstanding are also not included in the available float. These generally include treasury stock, stock options, equity participation units, warrants, preferred stock, convertible stock and rights.

For each component, S&P Dow Jones calculates an Investable Weight Factor ("**IWF**"), which represents the portion of the total shares outstanding that are considered part of the public float for purposes of the relevant Select Industry Index.

*Divisor.* Continuity in index values of each Select Industry Index is maintained by adjusting its divisor for all changes in its constituents' share capital after its base date. This includes additions and deletions to the relevant Select Industry Index, rights issues, share buybacks and issuances and non-zero price spin-offs. The value of each Select Industry Index's divisor over time is, in effect, a chronological summary of all changes affecting the base capital of that Select Industry Index. The divisor of each Select Industry Index is adjusted such that the index value of that Select Industry Index at an instant just prior to a change in base capital equals the index value of that Select Industry Index at an instant immediately following that change.

**Constituent Weightings**

At each quarterly rebalancing, constituents are initially equal weighted with adjustments to ensure that, for a given theoretical portfolio value ("**TPV**"), each constituent's weight in the relevant Select Industry Index does not exceed 4.5% of the FMC or the value that can be traded in three days. No stock can have a weight greater than 4.5% in the relevant Select Industry Index. TPVs are reviewed annually in September, incorporating index-linked exchange traded product assets under management ("**AUM**") using the below process:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Determine the maximum aggregate AUM tracking the relevant Select Industry Index over the past year, based on index-linked exchange traded product's AUM from the previous September, December, March and June, as well as the latest available month-end data point.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Round the maximum value up to the nearest billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Add a 20% buffer to the result and again round up to the nearest billion for the final TPV.

If there are no index-linked exchange traded products tracking the relevant Select Industry Index, the TPV for that index is set at US$2 billion. Any updates to the TPV for an index are made at the discretion of the Index Committee and announced to clients with ample lead time.

S&P Dow Jones Indices calculates a maximum constituent weight for each index constituent equal to the lesser of (i) 4.5%, (ii) 3 *times* the ratio of the three-month median daily value traded ("**MDVT**") of the index constituent to its TPV and (iii) 4.5% *times* the ratio of the index constituent's FMC to its TPV.

The reference date for assessing the 3-month MDVT and stock price is after the close on the last business day of February, May, August and November for the rebalancings effective after the close on the third Friday of March, June, September and December, respectively.

Each constituent's initial equal weight is compared to the calculated maximum constituent weight, and the constituent's weight is set to the lesser of the maximum constituent weight or the initial equal weight. If the resulting index weights do not sum to 100%, any excess weights are iteratively redistributed to the uncapped constituents.

If all constituents are capped and the resulting index weights still do not sum to 100%, the constraints are relaxed in the following order:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Maximum liquidity weight multiplier in increments of 0.1,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Single stock cap in increments of 0.1%,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. TPV decreasing in increments of US$100 million.

The process is repeated iteratively until a feasible solution is found. The single stock weight constraint's upper limit for the iterative process is 4.8%.

Accelerated Return Notes<sup>®</sup> TS-12

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

*Secondary Reweighting.* If, on the third to last business day of March, June, September or December, the aggregate weight of companies with index weights greater than 4.8% exceeds 50%, index weights reset to the previously determined weights using the data from that quarter's reference date, with an effective date as of after the close of the last business day of the month.

If a secondary reweighting is triggered, and existing constituent(s) were dropped since the prior quarterly rebalancing, the secondary reweighting re-runs the reweighting process using the same data from the latest quarterly rebalancing.

**Maintenance of the Select Industry Indices**

*Rebalancing.* The membership of the Select Industry Indices is reviewed quarterly. Rebalancings occur after the closing on the third Friday of the quarter ending month. The reference date for additions and deletions is after the closing of the last trading date of the previous month. Closing prices as of the Wednesday prior to the second Friday of the last month of the quarter are used for setting index weights.

*Additions.* Stocks are added between rebalancings only if a deletion in the applicable Select Industry Index causes the stock count to fall below 22. In those cases, each stock deletion is accompanied by a stock addition. The new stock will be added to the applicable Select Industry Index at the weight of the deleted company.

*Deletions.* A stock is deleted from the applicable Select Industry Index if the S&P TMI drops the stock. If a stock deletion causes the number of stocks in the applicable Select Industry Index to fall below 22, each stock deletion is accompanied by a corresponding stock addition. In the case of mergers involving two index constituents, the merged entity remains in the applicable Select Industry Index provided it satisfies the eligibility criteria. If the merged entity qualifies for index inclusion, the stock deemed the target is dropped, the index shares for the acquirer will remain unchanged, and the weightings of the remaining constituents adjust proportionally.

*GICS**<sup>®</sup>** Reclassifications.* If a constituent's GICS<sup>®</sup> classification changes to an ineligible sub-industry for a given Select Industry Index, the constituent is removed from that Select Industry Index at the subsequent rebalancing.

*Spin-Offs*. The S&P Select Industry Indices follow the S&P TMI treatment of spin-offs. In general, both the parent and spin-off company remain in the relevant Select Industry Index until the subsequent rebalancing. The spin-off company is added to the relevant Select Industry Index at a zero price at the close of the day before the ex-date. No price adjustment is applied to the parent and there is no divisor change. If the spin-off company is dropped from S&P TMI the weight of the spun-off company is added back to the parent stock's weight after at least one day of trading.

*Adjustments.* The table below summarizes the treatment of certain corporate actions.

---

| | |
|:---|:---|
| **Corporate Action**  | **Treatment**  |
| **Change in shares outstanding** | Shares outstanding changes are offset by an adjustment factor (AWF). There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment. |
| **Split/reverse split** | Shares outstanding are adjusted by the split ratio. Stock price is adjusted by the split ratio. There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment. |
| **Change in IWF** | IWF changes are offset by an AWF. There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment. |
| **Ordinary dividend** | When a company pays an ordinary cash dividend, the relevant Select Industry Index does not make any adjustments to the price or shares of the stock. As a result, there are no divisor adjustments to that Select Industry Index. |
| **Special dividend** | The stock price is adjusted by the amount of the dividend. The net change to the market capitalization of the relevant Select Industry Index causes a divisor adjustment. |
| **Rights offering** | All rights offerings that are in the money on the ex-date are applied under the assumption that the rights are fully subscribed. The stock price is adjusted by the value of the rights and the shares outstanding are increased by the rights ratio. The change in price and shares is offset by an AWF to keep the market capitalization (stock weight) of the relevant Select Industry Index unchanged. There is no change to the market capitalization of that Select Industry Index and no divisor adjustment. |

---

Accelerated Return Notes<sup>®</sup> TS-13

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

**Governance of the Select Industry Indices**

The Index Committee maintains the Select Industry Indices. All Index Committee members are full-time professional members of S&P Dow Jones's staff. The Index Committee meets regularly. At each meeting, the Index Committee reviews pending corporate actions that may affect the Select Industry Indices constituents, statistics comparing the composition of the Select Industry Indices to the market, companies that are being considered as candidates for addition to a Select Industry Index and any significant market events. In addition, the Index Committee may revise index policy covering rules for selecting companies, treatment of dividends, share counts or other matters.

Accelerated Return Notes<sup>®</sup> TS-14

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

***The following graph shows the daily historical performance of the Market Measure in the period from January 1, 2015 through December 18, 2025. We obtained this historical data from Bloomberg L.P. We have not independently verified the accuracy or completeness of the information obtained from Bloomberg L.P. On the pricing date, the Closing Market Price of the Market Measure was $120.01. The graph below may reflect adjustments in response to certain actions, such as stock splits and reverse stock splits.***

**Historical Performance of the Market Measure**

![](image_008.jpg)

***This historical data on the Market Measure is not necessarily indicative of the future performance of the Market Measure or what the value of the notes may be. Any historical upward or downward trend in the price per share of the Market Measure during any period set forth above is not an indication that the price per share of the Market Measure is more or less likely to increase or decrease at any time over the term of the notes.***

Before investing in the notes, you should consult publicly available sources for the prices of the Market Measure.

Accelerated Return Notes<sup>®</sup> TS-15

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Supplement to the Plan of Distribution

Under our distribution agreement with BofAS, BofAS will purchase the notes from us as principal at the public offering price indicated on the cover of this term sheet, less the indicated underwriting discount.

BofAS has advised us that MLPF&S will purchase the notes from BofAS for resale, and will receive a selling concession in connection with the sale of the notes in an amount up to the full amount of underwriting discount set forth on the cover of this term sheet.

We will pay a fee to LFT Securities, LLC for providing certain electronic platform services with respect to this offering, which reduces the economic terms of the notes to you. An affiliate of BofAS has an ownership interest in LFT Securities, LLC.

We will deliver the notes against payment therefor in New York, New York on a date that is greater than one business day following the pricing date. Under Rule 15c6-1 of the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes more than one business day prior to the original issue date will be required to specify alternative settlement arrangements to prevent a failed settlement.

The notes will not be listed on any securities exchange. In the original offering of the notes, the notes will be sold in minimum investment amounts of 100 units. If you place an order to purchase the notes, you are consenting to MLPF&S and/or one of its affiliates acting as a principal in effecting the transaction for your account.

MLPF&S and BofAS may repurchase and resell the notes, with repurchases and resales being made at prices related to then-prevailing market prices or at negotiated prices, and these prices will include MLPF&S's and BofAS's trading commissions and mark-ups or mark-downs. MLPF&S and BofAS may act as principal or agent in these market-making transactions; however, neither is obligated to engage in any such transactions. BofAS has advised us that, at MLPF&S's and BofAS's discretion, for a short, undetermined initial period after the issuance of the notes, MLPF&S and BofAS may offer to buy the notes in the secondary market at a price that may exceed the initial estimated value of the notes. Any price offered by MLPF&S or BofAS for the notes will be based on then-prevailing market conditions and other considerations, including the performance of the Market Measure, the remaining term of the notes and our creditworthiness. However, none of us, MLPF&S, BofAS or any of our respective affiliates is obligated to purchase your notes at any price or at any time, and we cannot assure you that we, MLPF&S, BofAS or any of our respective affiliates will purchase your notes at a price that equals or exceeds the initial estimated value of the notes.

The value of the notes shown on your account statement produced by MLPF&S will be based on BofAS's estimate of the value of the notes if BofAS or another of its affiliates were to make a market in the notes, which it is not obligated to do. That estimate will be based upon the price that BofAS may pay for the notes in light of then-prevailing market conditions and other considerations, as mentioned above, and will include transaction costs. At certain times, this price may be higher than or lower than the initial estimated value of the notes.

The distribution of the Note Prospectus in connection with these offers or sales will be solely for the purpose of providing investors with the description of the terms of the notes that was made available to investors in connection with their initial offering. Secondary market investors should not, and will not be authorized to, rely on the Note Prospectus for information regarding Barclays or for any purpose other than that described in the immediately preceding sentence.

Accelerated Return Notes<sup>®</sup> TS-16

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Structuring the Notes

The notes are our debt securities, the return on which is linked to the performance of the Market Measure. As is the case for all of our debt securities, including our market-linked notes, the economic terms of the notes reflect our actual or perceived creditworthiness at the time of pricing. The economic terms of the notes are based on our internal funding rates, which are our internally published borrowing rates based on variables such as market benchmarks, our appetite for borrowing and our existing obligations coming to maturity. Our internal funding rates may vary from the levels at which our benchmark debt securities trade in the secondary market. Our estimated value on the pricing date was based on our internal funding rates. Our estimated value of the notes may be lower if such valuation were based on the levels at which our benchmark debt securities trade in the secondary market.

At maturity, we are required to pay the Redemption Amount to holders of the notes, which will be calculated based on the $10 per unit principal amount and will depend on the performance of the Market Measure. In order to meet these payment obligations, at the time we issue the notes, we may choose to enter into certain hedging arrangements (which may include call options, put options or other derivatives) with BofAS or one of its affiliates. The terms of these hedging arrangements are determined by seeking bids from market participants, including MLPF&S, BofAS and their or our affiliates, and take into account a number of factors, including our creditworthiness, interest rate movements, the volatility of the Market Measure, the tenor of the notes and the tenor of the hedging arrangements. The economic terms of the notes and their initial estimated value depend in part on the terms of these hedging arrangements, any estimated profit that we or any of our affiliates expect to earn in connection with structuring the notes and estimated costs which we may incur in hedging our obligations under the notes.

BofAS has advised us that the hedging arrangements will include a hedging-related charge of approximately $0.05 per unit, reflecting an estimated profit to be credited to BofAS from these transactions. Since hedging entails risk and may be influenced by unpredictable market forces, additional profits and losses from these hedging arrangements may be realized by us, BofAS or any third party hedge providers.

For further information, see "Risk Factors—Valuation- and Market-related Risks" beginning on page PS-9 and "Use of Proceeds and Hedging" on page PS-23 of product supplement EQUITY ARN-1.

Accelerated Return Notes<sup>®</sup> TS-17

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Tax Consequences

You should review carefully the sections in the accompanying prospectus supplement entitled "Material U.S. Federal Income Tax Consequences—Tax Consequences to U.S. Holders—Notes Treated as Prepaid Forward Contracts" and, if you are a non-U.S. holder, "—Tax Consequences to Non-U.S. Holders." The following discussion, when read in combination with those sections, constitutes the full opinion of our special tax counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of the notes.

Based on current market conditions, in the opinion of our special tax counsel, it is reasonable to treat the notes for U.S. federal income tax purposes as prepaid forward contracts with respect to the Market Measure. Assuming this treatment is respected, upon a sale or exchange of the notes (including redemption at maturity), you should recognize gain or loss equal to the difference between the amount realized on the sale or exchange and your tax basis in the notes, which should equal the amount you paid to acquire the notes. Subject to the application of the constructive ownership rules, any gain or loss recognized on your notes should be treated as long-term capital gain or loss if you hold your notes for more than a year, whether or not you are an initial purchaser of notes at the issue price. The notes could be treated as constructive ownership transactions within the meaning of Section 1260 of the Code, in which case any gain recognized in respect of the notes that would otherwise be long-term capital gain and that was in excess of the "net underlying long-term capital gain" (as defined in Section 1260) would be treated as ordinary income, and a notional interest charge would apply as if that income had accrued for tax purposes at a constant yield over the notes' term. Our special tax counsel has not expressed an opinion with respect to whether the constructive ownership rules apply to the notes. Accordingly, U.S. holders should consult their tax advisors regarding the potential application of the constructive ownership rules.

The IRS or a court may not respect the treatment of the notes described above, in which case the timing and character of any income or loss on the notes could be materially and adversely affected. In addition, in 2007 the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal income tax treatment of "prepaid forward contracts" and similar instruments. The notice focuses in particular on whether to require investors in these instruments to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these instruments are or should be subject to the constructive ownership regime described above. While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You should consult your tax advisor regarding the U.S. federal income tax consequences of an investment in the notes, including the potential application of the constructive ownership rules, possible alternative treatments and the issues presented by this notice.

Treasury regulations under Section 871(m) generally impose a withholding tax on certain "dividend equivalents" under certain "equity linked instruments." A recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January 1, 2027 that do not have a "delta of one" with respect to underlying securities that could pay U.S.-source dividends for U.S. federal income tax purposes (each an "Underlying Security"). Based on our determination that the notes do not have a "delta of one" within the meaning of the regulations, our special tax counsel is of the opinion that these regulations should not apply to the notes with regard to non-U.S. holders. Our determination is not binding on the IRS, and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including whether you enter into other transactions with respect to an Underlying Security. You should consult your tax advisor regarding the potential application of Section 871(m) to the notes.

Accelerated Return Notes<sup>®</sup> TS-18

Accelerated Return Notes<sup>®</sup> <br> <u>Linked to the State Street<sup>®</sup> SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF, due February 26, 2027</u>

Validity of the Notes

In the opinion of Davis Polk & Wardwell LLP, as special United States products counsel to Barclays Bank PLC, when the notes offered by this pricing supplement have been issued by Barclays Bank PLC pursuant to the indenture, the trustee has made, in accordance with instructions from Barclays Bank PLC, appropriate entries or notations in its records relating to the master global note that represents such notes (the "master note"), and such notes have been delivered against payment as contemplated herein, such notes will be valid and binding obligations of Barclays Bank PLC, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith) and possible judicial or regulatory actions or application giving effect to governmental actions or foreign laws affecting creditors' rights, *provided* that such counsel expresses no opinion as to (i) the effect of fraudulent conveyance, fraudulent transfer or similar provision of applicable law on the conclusions expressed above or (ii) the validity, legally binding effect or enforceability of any provision that permits holders to collect any portion of the stated principal amount upon acceleration of the notes to the extent determined to constitute unearned interest. This opinion is given as of the date hereof and is limited to the laws of the State of New York. Insofar as this opinion involves matters governed by English law, Davis Polk & Wardwell LLP has relied, with Barclays Bank PLC's permission, on the opinion of Davis Polk & Wardwell London LLP, dated as of May 15, 2025, filed as an exhibit to the Registration Statement on Form F-3ASR by Barclays Bank PLC on May 15, 2025, and this opinion is subject to the same assumptions, qualifications and limitations as set forth in such opinion of Davis Polk & Wardwell London LLP. In addition, this opinion is subject to customary assumptions about the trustee's authorization, execution and delivery of the indenture and its authentication of the master note and the validity, binding nature and enforceability of the indenture with respect to the trustee, all as stated in the opinion of Davis Polk & Wardwell LLP, dated May 15, 2025, which has been filed as an exhibit to the Registration Statement referred to above.

Accelerated Return Notes<sup>®</sup> TS-19

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**F-3**

**BARCLAYS BANK PLC**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Debt | Global Medium-Term Notes, Series A | (1) | 457(r) | 2098702 | $10 | $20987020 | 0.0001381 | $2898.31 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $20987020 |  | 2898.31 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  | 0.00 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $2898.31 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) The filing fee paid with this filing pursuant to Rule 457(r) under the Securities Act of 1933, as amended (the "Securities Act"), was originally deferred in accordance with Rule 456(b) under the Securities Act.

**Narrative Disclosure**

The maximum aggregate offering price of the securities to which the prospectus relates is $20,987,020. The prospectus is a final prospectus for the related offering.